期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 17, 期 1, 页码 47-57出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1204234
关键词
Alzheimer's disease; synaptic dysfunction; amyloid beta; tau protein; neurogranin; biomarker; cerebrospinal fluid; pathophysiology; early diagnosis; precision medicine
资金
- AXA Research Fund
- Fondation Universite Pierre et Marie Curie
- 'Fondation pour la Recherche sur Alzheimer', Paris, France
- 'Investissements d'avenir' [ANR-10-IAIHU-06]
- Association for Alzheimer Research (Paris)
- Pierre and Marie Curie University (Paris)
- Pfizer Avid
Introduction: Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of Alzheimer's disease (AD). In addition, synaptic depletion closely correlates with clinical disease severity. Biomarkers that may track synaptic dysfunction in AD are eagerly awaited. Areas covered: Here, we reviewed the significance of the post-synaptic protein neurogranin - particularly enriched in dendritic spines - as a biomarker of early synaptic dysfunction in AD. We also examined its role as a marker to predict disease progression. Expert commentary: Current evidence indicates that neurogranin may serve as a mechanism-of-action biomarker aiding the in vivo investigation of AD-related pathophysiological pathways. Its use may support the development of targeted therapeutic interventions tailored to the individual patient, i.e. 'molecularly' targeted therapies, according to the evolving precision medicine paradigm.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据